Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734530 | 1.00 | NOS1 (0.45) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL23644553 | 0.85 | NOS1 (0.43) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL10432489 | 0.82 | CYP2C9 (0.40) | ALDH1A1LMNANPSR1CYP1A2CYP3A4 | |
| SCHEMBL28380319 | 0.82 | NOS1 (0.41) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL8989195 | 0.78 | HTR3E (0.41) | NOS1ALDH1A1NOS3LMNANOS2 | |
| Hydrochloric Acid SCHEMBL8989160 | 0.77 | HTR3E (0.40) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL7625151 | 0.77 | MAPT (0.47) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL29220713 | 0.74 | PTGS2 (0.48) | ALDH1A1LMNAMAPK1MAPTHTR3E | |
| SCHEMBL11982401 | 0.74 | CYP2C9 (0.48) | NOS1ALDH1A1NOS3LMNANOS2 | |
| SCHEMBL10119196 | 0.74 | CYP2C9 (0.48) | NOS1ALDH1A1NOS3LMNANOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | claimed |
| EP-2154132-A1 | A process for preparing tetrahydroquinoline derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | claimed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | claimed |
| CN-101466679-A | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-06-24 | — | — | CN | claimed |
| EP-2007728-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-12-31 | — | — | EP | claimed |
| WO-2007116922-A1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | WO | claimed |
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | disclosed |
| US-8084611-B2 | Process for preparing tetrahydroquinoline derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-27 | — | — | US | disclosed |
| EP-2007728-B1 | A PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131370-A1 | MELT-GRANULATED FINGOLIMOD | RATIOPHARM GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-2154132-A1 | A process for preparing tetrahydroquinoline derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| US-6489478-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INHIBITORS AND THE USE OF SUCH INHIBITORS TO ELEVATE CERTAIN PLASMA LIPID LEVELS, INCLUDING HIGH DENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER CERTAIN | PFIZER INC. | 2002-12-03 | — | — | US | disclosed |
| EP-1114032-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1114031-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6197786-B1 | ANTICHOLESTEROL AGENTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| US-6140343-A | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS WHICH ARE USED TO ELEVATE HIGHDENSITY LIPOPROTEIN-CHOLESTEROL AND TO LOWER LOW DENSITY LIPOPROTEIN-CHOLESTEROL AND TRIGLYCERIDES; FOR TREATING ATHEROSCLEROSIS, PERIPHERAL VASCULAR DISEASE, OBESITY | PFIZER (US) | 2000-10-31 | — | — | US | disclosed |
| WO-2000017165-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000017164-A1 | 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292125-A1 | PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES | PCSK9, LSS, DHCR7 | NOS1 212/4885ALDH1A1 2381/4885NOS3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.